海正药业：依维莫司片新增2.5mg规格获药品补充申请批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for a new specification of Everolimus tablets, which will enhance its market competitiveness in the oncology sector [1] Group 1: Product Approval - The company announced the approval of a supplementary application for Everolimus tablets, adding a new 2.5mg specification to the existing 5mg [1] - The new approval number is H20258293, with a validity period until 2030 [1] Group 2: Market Potential - The global sales forecast for Everolimus is approximately $1.013 billion in 2024, with domestic sales expected to be around $11.7842 million [1] - For the first half of 2025, global sales are projected to be about $497 million, with domestic sales around $5.4255 million [1] Group 3: Investment and R&D - The company has invested approximately $7.4042 million in the development of this new specification [1] - The approval is expected to enhance the company's competitive position in the market [1]